Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immunofluorescence Study

Simple Summary The introduction of immune-checkpoint inhibitors improved the therapeutic landscape for patients with advanced malignant melanoma. However, many patients, including patients with melanoma brain metastases, do not derive benefit from immune-checkpoint blockade. Hence, biomarkers are needed to identify potential mechanisms of resistance and optimize patient selection. This study aimed to explore the role of hypoxia-mediated immunosuppression within the tumor microenvironment of patients with metastatic melanoma using multiplex immunofluorescence. We analyzed the prognostic relevance of the hypoxia surrogate marker GLUT-1, the adenosine-synthesizing ectoenzymes CD73/CD39, and the infiltration by CD8 positive lymphocytes, and evaluated their spatial interaction within the tumor microenvironment (TME). Finally, we outlined the role of the melanoma immune phenotype for the patient’s prognosis and discussed the importance of tumor hypoxia and the adenosine system in shaping the tumor immune phenotype. Abstract Following the introduction of immune checkpoint inhibitors, a substantial prolongation of the overall survival has been achieved for many patients with multiple brain metastases from melanoma. However, heterogeneity between individual tumor responses is incompletely understood. In order to determine the impact of the individual tumor phenotype on the prognosis of melanoma patients, we examined surgical sections from 33 patients who were treated with radiotherapy (whole-brain radiotherapy, WBRT, stereotactic radiotherapy, STX, or both) and Ipilimumab. We analyzed multiplex staining of the hypoxia marker GLUT-1, the adenosine (ADO)-associated enzymes CD73 and CD39, and CD8, a marker of cytotoxic T lymphocytes (CTL) on a single-cell basis using QuPath. Additionally, the MOSAIC interaction analysis algorithm was used to explore the hypothesis that CTL systematically avoid GLUT-1high tumor areas. Our results revealed, that a strong GLUT-1 expression, low numbers of CTL, or exclusion of CTL from the tumor were correlated with significant prognostic detriment. Hypoxic tumors overall have smaller amounts of CTL, and spatial analysis revealed a repellent effect of hypoxia on CTL. In contrast to in vitro studies, specific upregulation of ADO-related enzymes CD73 and CD39 in GLUT-1high tumor regions was never observed. In this study, we could show direct in vivo evidence for hypoxia-mediated immunosuppression in melanoma. Moreover, this study suggests a significant prognostic relevance of the tumor immune phenotype, the strength of CD8 infiltration in the tumor, and the expression of hypoxia marker GLUT-1 on melanoma cells. Last, our results suggest a temporal stability of the microenvironment-mediated immunosuppressive phenotype in melanoma.

[1]  M. Cazzaniga,et al.  Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects , 2020, Cancers.

[2]  Piyushkumar A. Mundra,et al.  Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy , 2019, Nature Cancer.

[3]  M. Jarvis Therapeutic potential of adenosine kinase inhibition—Revisited , 2019, Pharmacology research & perspectives.

[4]  J. Deeks,et al.  Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer , 2019, Clinical Cancer Research.

[5]  Q. Fu,et al.  Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis , 2019, Oncoimmunology.

[6]  F. Mannavola,et al.  The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine , 2019, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[7]  Y. Najjar,et al.  Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. , 2019, JCI insight.

[8]  G. Tabatabai,et al.  Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. , 2019, Immunotherapy.

[9]  C. Loquai,et al.  Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters , 2018, Strahlentherapie und Onkologie (Print).

[10]  S. Patel,et al.  Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy , 2018, Front. Immunol..

[11]  P. Romero,et al.  CD73 expression and clinical significance in human metastatic melanoma , 2018, Oncotarget.

[12]  Kevin B. Kim,et al.  Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies , 2018, BMC Cancer.

[13]  S. Eichmüller,et al.  Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E , 2018, Front. Immunol..

[14]  A. Niemierko,et al.  The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity , 2018, Journal of Neuro-Oncology.

[15]  M. Smyth,et al.  Targeting immunosuppressive adenosine in cancer , 2017, Nature Reviews Cancer.

[16]  D. Schadendorf,et al.  Immunotherapy in melanoma: Recent advances and future directions. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[18]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[19]  H. Sugimura,et al.  Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer , 2017, Oncotarget.

[20]  P. Vaupel,et al.  Downregulation of EGFR in hypoxic, diffusion-limited areas of squamous cell carcinomas of the head and neck , 2016, British Journal of Cancer.

[21]  L. Nardo,et al.  Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. , 2016, The Journal of clinical investigation.

[22]  P. Darcy,et al.  Immunosuppressive activities of adenosine in cancer. , 2016, Current opinion in pharmacology.

[23]  P. Hegde,et al.  The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition , 2016, Clinical Cancer Research.

[24]  M. Maio,et al.  Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study , 2016, Oncoimmunology.

[25]  S. Biswas Metabolic Reprogramming of Immune Cells in Cancer Progression. , 2015, Immunity.

[26]  A. Ladányi,et al.  Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma , 2015, Pigment cell & melanoma research.

[27]  F. Malavasi,et al.  A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation , 2015, Oncotarget.

[28]  A. Bosserhoff,et al.  Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells , 2015, Oncotarget.

[29]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[30]  Akio Ohta,et al.  Immunological mechanisms of the antitumor effects of supplemental oxygenation , 2015, Science Translational Medicine.

[31]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[32]  N. Bec,et al.  Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity , 2014, Cancer Immunology Research.

[33]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[34]  J. Utikal,et al.  Extracellular adenosine metabolism in immune cells in melanoma , 2014, Cancer Immunology, Immunotherapy.

[35]  E. Rofstad,et al.  Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts , 2012, BMC Cancer.

[36]  J. Knisely,et al.  Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. , 2012, Journal of neurosurgery.

[37]  H. Moch,et al.  Tumor Cell Plasticity and Angiogenesis in Human Melanomas , 2012, PloS one.

[38]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[39]  B. Seliger,et al.  Warburg phenotype in renal cell carcinoma: High expression of glucose‐transporter 1 (GLUT‐1) correlates with low CD8+ T‐cell infiltration in the tumor , 2011, International journal of cancer.

[40]  P. Hwu,et al.  Prognostic factors for survival in melanoma patients with brain metastases , 2011, Cancer.

[41]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[42]  C. Garbe,et al.  Determinants of survival in patients with brain metastases from cutaneous melanoma , 2010, British Journal of Cancer.

[43]  A. Wree,et al.  Solid tumours arising from differently pre-oxygenated cells: Comparable growth rates despite dissimilar tissue oxygenation , 2009, International journal of radiation biology.

[44]  Jianzhu Chen,et al.  Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice , 2008, Proceedings of the National Academy of Sciences.

[45]  A. Wree,et al.  Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia. , 2008, Cancer research.

[46]  Michael Höckel,et al.  Detection and characterization of tumor hypoxia using pO2 histography. , 2007, Antioxidants & redox signaling.

[47]  Eva Mezey,et al.  Simultaneous Visualization of Multiple Antigens with Tyramide Signal Amplification using Antibodies from the same Species , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[48]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[49]  Johan Bussink,et al.  Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. , 2002, Cancer research.

[50]  S. Colgan,et al.  Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. , 2002, The Journal of clinical investigation.

[51]  G. Barnett,et al.  Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma , 2002, Cancer.

[52]  F. Eschwège,et al.  Intratumoral oxygen tension in metastatic melanoma , 1997, Melanoma research.

[53]  H. Lyng,et al.  Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[54]  C. Balch,et al.  Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. , 1986, Cancer research.

[55]  K. Hellström,et al.  Cellular and Humoral immunity to Different Types of Human Neoplasms , 1968, Nature.

[56]  Y. Kluger,et al.  Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  P. Dundr,et al.  Expression of Glut-1 in Malignant Melanoma and Melanocytic Nevi: an Immunohistochemical Study of 400 Cases , 2017, Pathology & Oncology Research.

[58]  P. Vaupel,et al.  Hypoxia-Driven Adenosine Accumulation: A Crucial Microenvironmental Factor Promoting Tumor Progression. , 2016, Advances in experimental medicine and biology.

[59]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .